174756-45-7 Usage
Description
2-Hydroxymethyl Olanzapine is a minor metabolite of Olanzapine, which is a pharmaceutical compound with a tan solid appearance. It is derived from the parent drug Olanzapine and possesses unique chemical properties that make it a subject of interest in various applications.
Uses
Used in Pharmaceutical Industry:
2-Hydroxymethyl Olanzapine is used as a minor metabolite for Olanzapine, which is an atypical antipsychotic medication. It plays a role in the overall pharmacological effects and safety profile of the drug, potentially contributing to its efficacy and side effects.
Used in Research and Development:
2-Hydroxymethyl Olanzapine is used as a research compound for studying the metabolism and pharmacokinetics of Olanzapine. Understanding the properties and behavior of this metabolite can help in the development of new drugs or the improvement of existing ones.
Used in Quality Control and Analysis:
2-Hydroxymethyl Olanzapine is used as a reference material for quality control and analytical purposes in the pharmaceutical industry. It helps ensure the purity, potency, and consistency of Olanzapine products by serving as a benchmark for comparison during testing and analysis.
Used in Radiolabelled Compounds:
2-Hydroxymethyl Olanzapine is used as a minor labelled metabolite in the development of radiolabelled compounds for imaging studies. This can aid in visualizing the distribution, metabolism, and excretion of Olanzapine in the body, providing valuable insights into its pharmacological behavior.
Check Digit Verification of cas no
The CAS Registry Mumber 174756-45-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,4,7,5 and 6 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 174756-45:
(8*1)+(7*7)+(6*4)+(5*7)+(4*5)+(3*6)+(2*4)+(1*5)=167
167 % 10 = 7
So 174756-45-7 is a valid CAS Registry Number.
InChI:InChI=1/C17H20N4OS/c1-20-6-8-21(9-7-20)16-13-10-12(11-22)23-17(13)19-15-5-3-2-4-14(15)18-16/h2-5,10,19,22H,6-9,11H2,1H3
174756-45-7Relevant articles and documents
Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3
Okubo, Maho,Narita, Momoko,Murayama, Norie,Akimoto, Youichi,Goto, Akiko,Yamazaki, Hiroshi
, p. 83 - 92 (2016/03/15)
Objective The antipsychotic olanzapine is reportedly metabolized by inducible human cytochrome P450 (CYP) 1A2 and variable copy-number CYP2D6 and polymorphic flavin-containing monooxygenase 3 (FMO3) in different pathways. We investigated individual differences in the metabolite formation and clearance of olanzapine in vitro and in vivo. Methods Human liver microsomal olanzapine oxidation activities were evaluated, and plasma concentrations of olanzapine were determined in 21 Japanese patients (mean age: 50 years, range: 32-69 years, 14 male and 7 female, including 6 smokers) genotyped for CYP2D6 (1,5, and10) and FMO3 (E158K, C197fsX, R205C, V257M, E308G, and R500X). Results Furafylline (a CYP1A2 inhibitor), quinidine (a CYP2D6 inhibitor), and heat treatment (inactivates FMO3) suppressed liver microsomal metabolic clearance of olanzapine by approximately 30%. Olanzapine N-demethylation and N-oxygenation were found to be catalyzed by CYP1A2 and CYP2D6 and by CYP2D6 and FMO3, respectively, in experiments using liver microsomes and recombinant enzymes. Plasma concentrations and clearance of olanzapine were not affected by CYP2D6 or FMO3 genotypes or smoking behavior. Conclusions Olanzapine clearance was not affected by CYP2D6 or FMO3 genotypes or smoking behavior as a single factor under the present conditions because olanzapine clearance is mediated by multiple enzymes involved in two major and one minor pathways.
